Biomarkers of VTE risk

Currently, there are no well-reognized predictive biomarkers incorporated into clinical practice that can identify those at high risk of first and recurrent VTE. By using targeted plasma proteome data from a large nested case-control study derived from the Tromsø study, we will identify biomarkers that are associated with risk of future VTE. We will perform protein quantitative loci (pQTL) analysis to identify genes that regulate biomarker levels, and assess potential causal associations between biomarkers and VTE by performing two-way Mendelian Randomization studies (using genetic data from the INVENT-consortium). Further, we will investigate the interaction between blood cell variables and biomarkers.

Principal Investigator: John-Bjarne Hansen

External collaborators: Pål Aukrust (Oslo University Hospital), Nicholas L Smith (University of Washington/INVENT consortium)

Publications:

Swamy et al. Plasma levels of P-selectin and future risk of incident venous thromboembolism. J Thromb Haemost. 2023; 21: 2451-60.

Hansen et al. Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism. JTH 2023.

Edvardsen et al. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism. J Thromb Haemost. 2023; 21: 1227-37.

Edvardsen et al. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv. 2021; 5: 224-32.

Edvardsen et al. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood. 2021; 138: 2269-77.

Ramberg et al. Plasma procoagulant phospholipid clotting time and venous thromboembolism risk. Res Pract Thromb Haemost. 2021; 5: e12640

Hansen et al. Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism. Thromb Res 2021;208:121-6.

Hansen et al. Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism. Blood 2020;136:1863-70.

Ellingsen et al. Plasma hepcidin is associated with future risk of venous thromboembolism. Blood Adv. 2018; 2: 1191-7.

North Norwegian Health Authority (Helse Nord)

Stiftelsen K.G. Jebsen